Abstract library

8 results for "Ardill".
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong
#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#580 Diagnostic Performance of Dual Tracer PET/CT in Staging Neuroendocrine Tumors of the Lung
Introduction: Different positron emission tomography/computed tomography (PET/CT) tracers may be useful in staging lung neuroendocrine tumors (LNETs)
Conference:
Category: Clinical
Presenting Author: Dr. Giorgio Treglia
#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr Rebecca Dobson
Authors: Dobson R, Burgess M, Chadwick C, Vora J, ...
#876 Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012)
Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Professor Joy E Ardill
Keywords: MGC
#878 Evidence of Improved Survival When Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management
Introduction: ENETs and UKINETs Guidelines emphasize that patients with NETs should be referred to NET specialist clinics (NSC) and these clinics should use a multidisciplinary team (MDT) for decision making. In Belfast there has been an NSC for several decades and an MDT since 2000.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy E Ardill
Authors: Ardill J E, McCance D, Johnston B, ...
Keywords: NET Clinics
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.